Shareholders Letter & Information Shareholder Letters Shareholders Letter 16 - May 2024 Shareholders Letter May 2023 (2) : GENFIT Shareholders Letter 15 Shareholders Letter May 2023 : GENFIT Shareholders Letter 14 Shareholders Letter May 2022 Shareholders' Letter, June 2021 Shareholders Letter, December 2020 Shareholders Letter, October 2019 Update on Corporate Governance, September 2019 Shareholders Letter, July 2019 Shareholders Letter, October 2017 Pagination Current page 1 Page 2 Next page next › Last page last » Information GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 GENFIT Reports Third Quarter 2024 Financial Information GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 GENFIT: May 22, 2024 Combined Shareholders Meeting Results GENFIT Reports First Quarter 2024 Financial Information Extra-Financial Performance Report 2024, 2023 Activity GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) GENFIT 2023 Annual Report on Form 20F GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F GENFIT Reports Full Year 2023 Financial Results and Provides Corporate Update GENFIT Announces 2024 Financial Calendar GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial 2023.12.08 - PR EN - GENFIT - 2024 outlook - FINAL Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023 GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine GENFIT Reports Third Quarter 2023 Financial Information GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023 GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update GENFIT to Participate in Upcoming Investor Conferences GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023 GENFIT: May 24, 2023 Combined Shareholders Meeting results GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology GENFIT Reports First Quarter 2023 Financial Information GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F GENFIT Reports Full-Year 2022 Financial Results and Provides Corporate Update GENFIT PR - 4Q financials 2022 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GENFIT Announces 2023 Financial Calendar GENFIT to Participate in Upcoming Investor Conferences GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting® GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases FDA Grants GENFIT’s GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GENFIT Reports First Quarter 2022 Financial Information GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022 GENFIT Annual Combined General Meeting of May 25, 2022 - Availability of Preparatory Documents GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update GENFIT: 2022 Financial Calendar GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program GENFIT: Third Quarter 2021 Financial Information New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting® GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GENFIT: June 30, 2021 Annual Shareholders Meeting results GENFIT obtains non-dilutive financing of €11 million in the form of a State Guaranteed Loan GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021 GENFIT Provides Pipeline Update and Launch of New Clinical Programs GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021 GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update GENFIT appoints Jean-François Tiné to the Board of Directors GENFIT: new market research data highlight potential of elafibranor in PBC GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology GENFIT Announces Two Key Appointments to the Executive Committee GENFIT: Technical Corrections to the Results of the January 25, 2021 Bondholders Meeting with No Impact on Resolutions’ Approval GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 GENFIT: January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021 GENFIT to Present at Upcoming Investor Conferences and Host a PBC KOL Event GENFIT: Renegotiation of the OCEANEs Convertible Bond Terms: Availability of Prospectus Relating to the Admission of New Shares Following Conversion of the OCEANEs GENFIT announces the successful completion of a key milestone in the partial buyback and amendment of its OCEANEs GENFIT announces satisfactory preliminary results of its OCEANEs’ partial buyback offer GENFIT Announces Final Terms For Proposed Renegotiation of 2022 OCEANE Convertible Bonds GENFIT: Third Quarter 2020 Financial Information and Launch of Renegotiation of Convertible Bond GENFIT: New Data Presented at AASLD The Liver Meeting Digital Experience™ GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Strategy on September 30, 2020 GENFIT Announces Two Oral Presentations at the Digital International Liver Congress™ 2020 GENFIT Announces Pivotal Publication of NIS4™ Technology to Identify Patients with At-Risk NASH in The Lancet Gastroenterology & Hepatology GENFIT: Provides Initial Update on Corporate Strategy GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial GENFIT: Enhances Board of Directors with Two Strategic Appointments GENFIT: June 30, 2020 Annual Shareholders Meeting results GENFIT: Information relating to the shareholders meeting of June 11, 2020 GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis GENFIT: Updates to 2020 Financial Calendar GENFIT: Update on Regulatory and Clinical Activities Amid the COVID-19 Pandemic GENFIT Answers Investors’ Questions Raised Today - January 23, 2020 Information note – GENFIT: Cymabay Phase 2 data: read-across for RESOLVE-IT? – June 11, 2019 GENFIT: Clarification of Erroneous Trading Information (update Dec 21, 2018 – 08:30 pm CET), December 2018 2020.02.20 GENFIT PR - FDA 2020.02.20 GENFIT CP - FDA
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023
GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology
GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program
GENFIT Announces Publication of the 2022 Universal Registration Document and the 2022 Annual Report on Form 20-F
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis
GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases
GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership
GENFIT: FNIH NIMBLE Study Demonstrates NIS4® Technology’s Unique Performance in Identifying Patients with “at-risk” NASH
GENFIT Announces First Patient First Visit for the Evaluation of NTZ in Subjects with Hepatic Impairment as part of its ACLF Program
New Clinical Data on GENFIT’s Investigational Compound Elafibranor to be Presented at AASLD The Liver Meeting®
GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association
GENFIT: June 15, 2021 Combined Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening
GENFIT Informs its Shareholders of Certain Procedures for the Combined General Meeting of June 15, 2021
GENFIT announces the launch by Labcorp of NASHnext® A Novel Noninvasive Diagnostic Test Powered by GENFIT’s NIS4™ Technology to Identify Patients with At-Risk NASH
GENFIT: Publication of the 2020 Universal Registration Document and the 2020 Annual Report on Form 20-F; Annual Shareholders Meeting to take place on June 15, 2021
GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology
GENFIT: Technical Corrections to the Results of the January 25, 2021 Bondholders Meeting with No Impact on Resolutions’ Approval
GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021
GENFIT: January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the resolutions submitted to the shareholders’ vote but quorum not met on first convening
GENFIT Informs its Shareholders of Certain Procedures for the Extraordinary General Meeting of January 13, 2021
GENFIT: Renegotiation of the OCEANEs Convertible Bond Terms: Availability of Prospectus Relating to the Admission of New Shares Following Conversion of the OCEANEs
GENFIT announces the successful completion of a key milestone in the partial buyback and amendment of its OCEANEs
GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease
GENFIT To Announce First Half-Year 2020 Financial Results and New Corporate Strategy on September 30, 2020
GENFIT Announces Pivotal Publication of NIS4™ Technology to Identify Patients with At-Risk NASH in The Lancet Gastroenterology & Hepatology
GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis
GENFIT: Clarification of Erroneous Trading Information (update Dec 21, 2018 – 08:30 pm CET), December 2018
